GB Sciences Co-Authors a Peer-Reviewed Article Showing that Heart Failure Can Be Mitigated, and Reversed, by Orally Administered Drugs Targeting a Cellular Cannabinoid Receptor

Pioneering new scientific research in the publication, Channels, explains the promise of targeting the ionotropic cannabinoid receptor TRPV1, for the treatment and reversal of heart failure.

LAS VEGAS, Nov. 27, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) is pleased to announce the publication of a research article co-authored by GB Sciences and key collaborators in the peer-reviewed journal Channels, which explains the potential medical benefits of using cannabinoid receptor-targeting therapies for the treatment of heart disease. GB Sciences’ own Chief Science Officer, Dr. Andrea Small-Howard, joins co-authors including University of Hawaii faculty member and President of Makai more at